Main Article Content
Heart failure is increasing in prevalence and represents a significant burden to the Canadian Health Care System. To provide optimal care for this complex disease, a multi-faceted approach is required, leveraging all available pharmacologic therapies, invasive and device-based treatments. Within the Canadian context, patients should ideally be managed in collaboration with multidisciplinary chronic disease management programs, and be appropriately referred for advanced therapies where indicated. In this article, we aim to provide guidance on patient risk stratification, application of guideline-directed medical therapy for heart failure with preserved and reduced ejection fraction, and provide guidance on patient suitability for heart failure specific devices and advanced therapies.